Clinical trials: Normal Responders
Rheumatoid Arthritis
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
This multicenter, prospective, observational study will assess the efficacy of MabThera/Rituxan (rituximab) and alternative TNF-inhibitors in patients with rheumatoid arthritis who are non-responders or intolerant to a single…
- Trial name
- NCT01557348
- Where
- 215 sites in Canada, Colombia and 10 more
- Volunteers
- 1,239 people
- Sponsor
- Hoffmann-La Roche
Inflammation, Rheumatoid Arthritis
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
This trial is conducted in Europe, North America and South America. The aim of this trial is to investigate the clinical efficacy of NNC0109-0012, a human monoclonal antibody, compared to placebo when administered as weekly…
- Trial name
- NCT01636843
- Testing
- NNC0109-0012
- Where
- 139 sites in United States, Argentina and 12 more
- Volunteers
- 298 people
- Sponsor
- Novo Nordisk A/S
Breast Cancer, Breast Biopsy
Vacuum Assisted Biopsy and Surgery Correlation in HER2 and TN Breast Cancer Subtypes MRI Responders After Neoadjuvant Therapy: BISUCO TRIAL
BACKGROUND AND CURRENT STATUS: Advancements in neoadjuvant systemic treatments (NST) for HER2 positive and triple-negative (TN) breast cancer (BC) subtypes have led to high rates of pathologic complete response (pCR), raising…
- Trial name
- BISUCO (NCT06371989)
- Testing
- Image guided vacuum assisted biopsy
- Where
- Spain
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Hospital Universitario 12 de Octubre
Arthritis, Rheumatoid
COBRA-Slim With or Without Fast Access to TNF Blockade for Remission Induction in Early RA
In the Care in Rheumatoid Arthritis (CareRA) trial (NCT01172639) about 70% of early RA patients are in remission at the 2 year evaluation point independent of the combination scheme used.
- Trial name
- CareRA2020 (NCT03649061)
- Testing
- Etanercept 50 MG/ML, Leflunomide 10 milligram (MG)
- Where
- 19 sites in Belgium
- Volunteers
- 276 people
- Sponsor
- P. Verschueren
Ovarian Response
Androgens for Poor Responders in In Vitro Fertilization
it has been shown that androgens in non human primates may favour follicular growth in the ovaries when animals are treated with gonadotropins which are the hormones used in patients receiving treatment with in vitro…
- Trial name
- NCT00693108
- Testing
- Transdermal testosterone
- Where
- Spain
- Sponsor
- Hospital Clinic of Barcelona
HNSCC
WGA in Platinum-refractory HNSCC Underwent Nivolumab
To choose a subgroup who could clearly benefit from Nivolumab, we are proposing a prospective observational study. Whole-genome study (WGS) analysis will be performed on archived cancer tissues from patients who were (1)…
- Trial name
- NCT03917537
- Testing
- HNSCC patients have used Nivolumab
- Where
- 2 sites in Taiwan
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Osteosarcoma, Ewing Sarcoma
Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse
Primitive bone sarcoma are rare tumors with low options of therapy for patient treatment. 1. OSTEOSARCOMA VERY POOR RESPONDER COHORT.
- Trial name
- Metform-Bone (NCT04758000)
- Testing
- Metformin Hydrochloride
- Where
- Italy
- Volunteers
- 67 people
- Sponsor
- Istituto Ortopedico Rizzoli
Ewing's Sarcoma
Post-operative Radiotherapy in Poor Responders Ewing's Sarcoma Patients
Local recurrence after surgical resection is a complex phenomenon. An important predictive factor is the response to chemotherapy. Central site of disease may be a second independent predictive factor (Lin et al. 2007).
- Trial name
- NCT01734863
- Testing
- External Beam Radiotherapy
- Where
- Egypt
- Sponsor
- Children's Cancer Hospital Egypt 57357
Rheumatoid Arthritis
To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)
Primary Objective: To demonstrate that sarilumab added to disease modifying anti-rheumatic drugs (DMARDs) were effective for: reduction of signs and symptoms at Week 24 and improvement of physical function at Week 12 in…
- Trial name
- NCT01709578
- Testing
- Sarilumab, hydroxychloroquine, methotrexate
- Where
- 196 sites in United States, Argentina and 28 more
- Volunteers
- 546 people
- Sponsor
- Sanofi
Moderate to Severe Plaque-type Psoriasis
Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis
This study is designed to support the optimal use of secukinumab by providing data to refine guidance on dosing flexibility in patients with psoriasis.
- Trial name
- GAIN (NCT02474069)
- Testing
- Secukinumab
- Where
- 89 sites in Germany
- Volunteers
- 772 people
- Sponsor
- Novartis Pharmaceuticals
Adolescents, Physical Activity
School-based HIIT and Dose-Response Effects
There are experimental evidences of the importance of high intensity exercises in health outcomes improvement. However, there are limited knowledge about possibility to affect health outcomes in adolescents through exercises…
- Conditions
- Adolescents, Physical Activity, Adipose Tissue, Blood Pressure
- Trial name
- PEER-HEART (NCT06431230)
- Testing
- standard high-intensity interval training, plyometric high-intensity interval training
- Where
- Poland
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Wroclaw University of Health and Sport Sciences
Peyronie's Disease
Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders
Compare key clinical outcomes between controls and men treated with a novel CCH administration protocol among men previously unresponsive to CCH administration.
- Trial name
- NCT05108558
- Testing
- CCH administration, Control - Crossover to CCH, RestoreX
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Charitable Union for the Research and Education of Peyronie's Disease
Malignant Neoplasm
Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment
This pilot research trial studies molecular profiling in tissue samples from patients with cancer who got better with treatment that didn't work for most other patients with the same disease.
- Trial name
- NCT02243592
- Testing
- Laboratory Biomarker Analysis
- Where
- 73 sites in United States
- Volunteers
- 170 people
- Sponsor
- National Cancer Institute (NCI)
Plaque-type Psoriasis
Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis
The study will assess the safety and efficacy of intravenous (10mg/kg) and subcutaneous (300mg) secukinumab in moderate to severe chronic plaque-type psoriasis who are partial responders to secukinumab.
- Trial name
- STATURE (NCT01412944)
- Testing
- secukinumab 150mg, secukinumab 10mg/kg i.v. regimen
- Where
- 27 sites in United States, Austria and 6 more
- Volunteers
- 43 people
- Sponsor
- Novartis Pharmaceuticals
Ovarian Stimulation
Serum FSH Monitoring for Identification of an Optimal Range During Ovarian Stimulation
This study examines if monitoring serum Follicle Stimulation Hormone (FSH) levels can predict oocyte yield and progesterone levels, considering factors like age, baseline FSH, Antral Mullerian Hormone (AMH), antral follicle…
- Trial name
- FSH (NCT06572930)
- Testing
- Gonal-f (gonadotropin)
- Where
- United Arab Emirates
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- ART Fertility Clinics LLC
Inflammation, Rheumatoid Arthritis
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
This trial is conducted in Europe, North America and South America. The aim of this trial is to investigate the clinical efficacy of NNC0109-0012, a human monoclonal antibody, compared to placebo when administered as weekly s.c.
- Trial name
- NCT01636817
- Testing
- NNC0109-0012
- Where
- 164 sites in United States, Argentina and 11 more
- Volunteers
- 239 people
- Sponsor
- Novo Nordisk A/S
Hydrocephalus, Normal Pressure
Using Cerebrospinal Fluid Dynamics to Optimize Treatment of Idiopathic Normal Pressure Hydrocephalus
The purpose of the study is to determine if the so called pulsatility curve, which describes the relationship between intracranial pressure (ICP) and ICP pulsatility, can be used to predict outcome of treatment, in the form of…
- Trial name
- PULSE-OPT (NCT03076723)
- Testing
- Change in shunt opening pressure, Simulated change in shunt opening pressure
- Where
- 5 sites in Finland, Sweden
- Volunteers
- 43 people
- Sponsor
- Umeå University
Lupus Nephritis
A Study to Evaluate the Efficacy and Safety of Tacrolimus With Steroid in Korean Lupus Nephritis Patients
This study is to evaluate efficacy and safety of tacrolimus with steroid by observing remission rate at 24 weeks in lupus nephritis patients who are non-responders to steroid monotherapy.
- Trial name
- APPLE (NCT01316133)
- Testing
- tacrolimus
- Where
- 7 sites in South Korea
- Volunteers
- 37 people
- Sponsor
- Astellas Pharma Korea, Inc.
Cutaneous Melanoma, Mucosal Melanoma
Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)
This clinical trial is for patients with stage 3 cutaneous melanoma and patients with mucosal melanoma who are able to have surgery to remove all tumour deposits.
- Trial name
- Neo IRENIE (NCT06999980)
- Testing
- Ipilimumab 3mg/kg and nivolumab 1mg/kg, Ipilimumab 1mg/kg Nivolumab 480mg and relatlimab 160mg, Nivolumab 480mg and relatlimab 160mg
- Where
- Australia
- Volunteers
- 494 people
- Sponsor
- Melanoma Institute Australia
Rheumatoid Arthritis
Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients
Primary Objectives: Part A (dose ranging study): To demonstrate that sarilumab (SAR153191/REGN88) on top of MTX was effective on reduction of signs and symptoms of rheumatoid arthritis at 12 weeks.
- Trial name
- RA-MOBILITY (NCT01061736)
- Testing
- Sarilumab, Methotrexate, Folic Acid
- Where
- 262 sites in United States, Argentina and 34 more
- Volunteers
- 1,675 people
- Sponsor
- Sanofi